With human consortia, Illumina helps biomedical researchers from across the world work together to design and run custom genomics assays. Illumina coordinates, members pool resources, and everyone benefits.
Consortia products include high-powered genotyping arrays and other next-generation genetic analysis tools. Human consortia may be open or confidential. From custom content to project management and bioinformatics, Illumina offers a comprehensive solution for human consortia members.
Illumina microarrays support high-throughput, multiplex processing, making them ideal for large-scale population study researchers and biobanks performing genome-wide association studies. The following are our currently open human consortia arrays and array products.
This consortium developed a highly economical array for population-scale genomics and genetic risk screening. The Global Screening Array combines a universal genome-wide backbone optimized for high imputation accuracy, with hand-curated clinical research variants designed against the breadth of functional variation.
Consortium members include Ben Neale from the Broad Institute, who develops statistical methods for analyzing genetic data. Millions of samples will be screened, with global participation from over 200 members from 55 institutions, including biobanks, clinical researchers, pharmaceutical companies, and health care providers.
The H3Africa Consortium seeks to empower researchers with leading-edge genomics tools to study environmental and genetic factors that play a role in disease susceptibility and drug responses. With novel, genome-wide content from individuals across African populations, and built on the MEGA Array backbone, the H3Africa Consortium Array1 is designed to be an effective and comprehensive array for the study of African Genomics. H3Africa data will inform strategies to address health inequity and will lead to health benefits in Africa and beyond.
This genotyping array was developed in collaboration with leaders in translational genomics and computational biology. It enables researchers to more effectively screen potential drug targets earlier in the development process. Learn more about this consortium.
Partners from the neurogenomics community designed the Neuro Consortium Array to fine map and interrogate the genomics of neurodegenerative diseases. The consortium gathered all identified markers found in known neurodegenerative disease genes, to include in a single genotyping array.
This consortium-built array family delivers increased power for understanding complex disease in diverse human populations. It provides a cost-effective method for large-scale population research with excellent genomic coverage and high-value, expert-selected content. Learn more about this consortium.